UK Launch of LVOne Stroke Triage Test by UpFront Diagnostics
Abingdon Health updates on collaboration with 4TEEN4 Pharmaceuticals
Abingdon Health plc (AIM: ABDX) has provided an update on its partnership with 4TEEN4 Pharmaceuticals GmbH, focused on the co-development of a companion diagnostic for a potentially life-saving shock therapy.
Abingdon Health plc (AIM: ABDX) $2.5m Contract for clinical self-test development
$2.5m Contract Award for development of clinical self-test
Abingdon Health plc (AIM: ABDX) c.US$2m multiplex diagnostic test contract win
c.US$2m multiplex diagnostic test contract win Development, scale-up and technical transfer for a semi-quantitative, multiplex lateral flow test system
genedrive plc (AIM: GDR) MT-RNR1 ID Kit in Dublin’s Rotunda Hospital
Genedrive® MT-RNR1 ID Kit implemented at Dublin’s Rotunda Hospital
Genedrive Shares Jump 22% on Talks Over £1 Million Shareholder Loan
Genedrive PLC (AIM: GDR) shares soared 22% to 1.04p after the diagnostics company confirmed it is in talks with major shareholder David Nugent regarding a potential £1 million loan to
genedrive plc (AIM: GDR) Comment re: Share Price Movement
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, notes the fall in the Company’s share price on 13 August 2025 which it believes was connected to postings
genedrive PLC (AIM: GDR) Expects Revenue to Double as Commercial Momentum Builds
Genedrive PLC (AIM: GDR), the developer of rapid genetic testing technology, expects total income for the year ended 30 June to rise to around £1 million, up from £0.5 million
Abingdon Health plc (AIM: ABDX) Trading update
Revenue for FY25 in line with market expectations of £8.6m Continued strong revenue growth anticipated in FY26
Abingdon Health plc (AIM: ABDX) c. US$2.5m companion diagnostic test contract win
c. US$2.5m companion diagnostic test contract win Full CDMO service contract for development, scale-up, technical transfer, manufacture and full regulatory support
Genedrive PLC (AIM:GDR) received European regulatory approval
Genedrive wins EU approval for rapid genetic test aimed at stroke and heart attack care
Genedrive PLC (AIM:GDR) CYP2C19-ID Kit adopted for routine clinical use
North West Anglia Foundation NHS Trusts’ Peterborough City Hospital implements the Genedrive® CYP2C19-ID Kit for routine clinical use